[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579450":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":18,"locations":29,"responsibleParty":49,"collaborators":18,"id":52,"slug":18,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Participants receive Dipyridamole in addition to standard post-transplant care.",[13],"Drug: Dipyridamole 75 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants in this group will receive standard post-transplant care without Dipyridamole.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Dipyridamole 75 MG","Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg\u002FdL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.",[9],[26],{"name":27,"affiliation":5,"role":28},"Stephan Busque, MD","PRINCIPAL_INVESTIGATOR",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Stanford","California","94304","United States",{"type":37,"coordinates":38},"Point",[39,40],-122.16608,37.42411,{"lat":40,"lon":39},[43,48],{"name":44,"role":45,"phone":46,"phoneExt":18,"email":47},"Pari Waghela, MS","CONTACT","650-724-8441","pariw@stanford.edu",{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":28,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Stephan Busque","Professor of Surgery (Abdominal Transplantation)","100579450",false,"NCT06824454","Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients","Inclusion Criteria:\n\n* Adult kidney transplant patients.\n* No known contraindications to Dipyridamole\n\nExclusion Criteria:\n\n* Contraindications to Dipyridamole.\n* Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).\n* Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.","ALL","18 Years",{"count":60,"type":61},90,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.",[67,68],"Hypophosphatemia","Kidney Transplantation",[70,71,72,73,74,75,76],"Post-kidney transplant care","Dipyridamole","Renal phosphate loss","Serum phosphate levels","Phosphate supplementation","Transplant graft function","Kidney transplant complications","2026-06-09",{"date":79,"type":80},"2026-06-11","ACTUAL",{"date":82,"type":80},"2025-05-15",{"date":84,"type":61},"2027-05",{"name":5,"class":6},1]